Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27149274 | 0.83 | AAK1 (0.38) | SSTR4GAA | |
| SCHEMBL30012981 | 0.83 | AAK1 (0.38) | SSTR4GAA | |
| SCHEMBL15467385 | 0.82 | SYK (0.35) | — | |
| SCHEMBL29013097 | 0.81 | MAPT (0.31) | — | |
| SCHEMBL15467427 | 0.77 | HTT (0.31) | MET | |
| SCHEMBL22711967 | 0.76 | — | — | |
| SCHEMBL322917 | 0.74 | PIK3CA (0.41) | — | |
| SCHEMBL29217722 | 0.74 | MAPT (0.32) | — | |
| SCHEMBL20209642 | 0.72 | SSTR4 (0.36) | SSTR4RXRAGRIN1GRIN2B | |
| SCHEMBL20746486 | 0.72 | MET (0.35) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11918571-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240043433-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3801535-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| CN-112423760-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200377506-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377507-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918571-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN2A | MET 4242/4885SSTR4 3842/4885GAA 935/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | MET 4314/4885SSTR4 2960/4885GAA 3554/4885 |
| US-20200377506-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | MET 3724/4885SSTR4 3315/4885GAA 832/4885 |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN5A | MET 4836/4885SSTR4 4386/4885GAA 2433/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20210163488-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20240043433-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20210171530-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | MET 4014/4885SSTR4 1205/4885GAA 2695/4885 |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | SCN3A, SCN1A, SCN5A | MET 3899/4885SSTR4 3365/4885GAA 3871/4885 |
| US-20200377507-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | MET 4813/4885SSTR4 3779/4885GAA 1267/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MET 3989/4885SSTR4 3868/4885GAA 2007/4885 |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | MET 4242/4885SSTR4 3842/4885GAA 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.